The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis
Abstract
PURPOSE: To analyze whether bevacizumab can inhibit inflammatory angiogenesis and lymphangiogenesis in the cornea. Bevacizumab (Avastin; Roche, Welwyn Garden City, UK) is a recombinant, humanized, monoclonal antibody against VEGF-A that has been approved by the U.S. Food and Drug Administration for the treatment of colon carcinomas. METHODS: The mouse model of suture-induced corneal neovascularization was used to assess the antihemangiogenic and antilymphangiogenic effect of bevacizumab by systemic and topical application. Corneal flatmounts were stained with LYVE-1 as a specific lymphatic vascular endothelial marker and CD31 as a pan-endothelial marker, and blood and lymph vascularized areas were analyzed morphometrically. The inhibitory effect of bevacizumab on lymphatic endothelial cells (LECs) was analyzed with a colorimetric (BrdU) proliferation ELISA. The binding ability of bevacizumab to murine VEGF-A was analyzed by Western blot, ELISA, and surface plasmon resonance. RESULTS: The systemic and topical applications of bevacizumab significantly inhibited the outgrowth of blood (P < 0.006 and P < 0.0001, respectively) and lymphatic (P < 0.002 and P < 0.0001, respectively) vessels. Inhibition of the proliferation of LECs was also significant (P < 0.0001). Western blot analysis, ELISA, and the surface plasmon resonance assay showed that bevacizumab binds murine VEGF-A. CONCLUSIONS: Topical or systemic application of bevacizumab inhibits both inflammation-induced angiogenesis and lymphangiogenesis in the cornea. This finding suggests an important role of VEGF-A in corneal lymphangiogenesis. Bevacizumab may be useful in preventing immune rejections after penetrating keratoplasty or tumor metastasis via lymphatic vessels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., & Detmar, M. (2001) · Nature Medicine · doi:10.1038/84643 · Cited by 1,733
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Lymphangiogenesis in development and human disease
Alitalo, K., Tammela, T., & Petrova, T. V. (2005) · Nature · doi:10.1038/nature04480 · Cited by 1,285
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Cursiefen, C., Chen, L., Borges, L. P., Jackson, D. G., Cao, J., Radziejewski, C. H., D'Amore, P. A., Dana, M. R., Wiegand, S. J., & Streilein, J. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420465 · Cited by 1,059
Self-citationSchacht, V., Dadras, S. S., Johnson, L. A., Jackson, D. G., Hong, Y.-K., & Detmar, M. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62311-5 · Cited by 596
Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021244 · Cited by 559
Endogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553
He, Y., Kozaki, K.-I., Karpanen, T., Koshikawa, K., Yla-Herttuala, S., Takahashi, T., & Alitalo, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.819 · Cited by 521
Lymphangiogenesis and tumor metastasis: myth or reality?
Pepper, M. S. (2001) · PubMed · Cited by 366
Cited by
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Hos, D., Matthaei, M., Bock, F., Maruyama, K., Notara, M., Clahsen, T., Hou, Y., Le, V. N. H., Salabarria, A.-C., Horstmann, J., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.001 · Cited by 303
Self-citationXiao, L., Yan, K., Yang, Y., Chen, N., Li, Y., Deng, X., Wang, L., Liu, Y., Mu, L., Li, R., et al. (2016) · Microvascular Research · doi:10.1016/j.mvr.2016.01.005 · Cited by 20
Antiangiogenesis Effect of Albendazole on the Cornea
Cho, Y. K., Shin, E. Y., Uehara, H., & Ambati, B. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0103 · Cited by 7
Metadata
- Authors
- Bock, F., Onderka, J., Dietrich, T., Bachmann, B., Kruse, F. E., Paschke, M., Zahn, G., & Cursiefen, C.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2007-06-01
- Volume
- 48
- Issue
- 6
- Pages
- 2545
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2090093512
- Cited by
- 320
- References
- 25
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis. https://app.cochat.ai/papers/10.1167/iovs.06-0570
- The paper
- Bock, F., Onderka, J., Dietrich, T., Bachmann, B., Kruse, F. E., Paschke, M., Zahn, G., & Cursiefen, C. (2007). Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.06-0570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
